

Urgent Care Association of America



Myles D. Greenberg, M.D., M.B.A.
Partner, CHL Medical Partners

Dr. Greenberg is a Partner with CHL Medical Partners. CHL Medical Partners is a healthcare venture capital firm based in Stamford, CT, investing in start-up and early-stage private companies in biotechnology, diagnostics, medical devices, and healthcare services. CHL currently manages over \$300 million in assets and approximately 20 active portfolio companies. Previous to joining CHL, Dr. Greenberg was Senior Principal at A. M. Pappas & Associates in Research Triangle Park, NC (now Pappas Ventures) and held a faculty appointment as an Assistant Professor at the University of North Carolina School of Medicine. Prior to joining the venture capital industry, he was Assistant Clinical Director in the Department of Emergency Medicine at Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA.

Dr. Greenberg has served on the Boards of Directors in a number of venture-backed healthcare companies, including Angiomics (acquired by PDL), NuVasive (Nasdaq: NUVA), and Syntonix (acquired by Biogen Idec). He currently serves on the boards of five CHL Medical Partners portfolio companies: Millennium Pharmacy Systems, Oriel Therapeutics, Paringenix, Still River Systems, and Vertos Medical.

Dr. Greenberg received his B.A.S. from the University of Pennsylvania School of Engineering and Applied Science. He holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Harvard Business School. He completed residency training in Emergency Medicine at the University of Pittsburgh and is a Diplomate of the American Board of Emergency Medicine.

Contact Information:

Myles Greenberg
CHL Medical Partners
mgreenberg@chlmedical.com